Safety and Efficacy Study of PTK787/ZK222584 to Treat Metastatic Neuroendocrine Tumors
Status:
Completed
Trial end date:
2010-10-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to examine if PTK787/ZK222584 (vatalanib) will stabilize or
decrease rising biochemical markers along with progressive disease or syndrome symptoms in
patients with metastatic neuroendocrine tumors.
Phase:
Phase 2
Details
Lead Sponsor:
Louisiana State University Health Sciences Center in New Orleans University of Iowa